Vir Biotechnology, Inc. Collaboration Agreements
17 Contracts & Agreements
- Amendment No. 1 to the Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited dated May 27, 2022 (Filed With SEC on August 9, 2022)
- Preliminary Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated February 14, 2021 (Filed With SEC on May 6, 2021)
- Development and Manufacturing Collaboration Agreement between the Company and Wuxi Biologics (Hong Kong) Limited, dated February 25, 2020 (Filed With SEC on July 6, 2020)
- Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited and Beecham S.A., dated June 9, 2020 (Filed With SEC on July 6, 2020)
- Preliminary Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated April 5, 2020 (Filed With SEC on July 6, 2020)
- Amendment No. 3 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated April 1, 2020 (Filed With SEC on July 6, 2020)
- Amendment No. 2 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated March 3, 2020 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (Filed With SEC on March 26, 2020)
- Collaboration, Option, and License Agreement between the Registrant and Brii Biosciences Limited (previously named BiiG Therapeutics Limited), dated May 23, 2018 (Filed With SEC on September 3, 2019)
- Amendment 6 to Sub-License and Collaboration Agreement, dated September 7, 2018, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated... (Filed With SEC on September 3, 2019)
- Amendment 5 to Sub-License and Collaboration Agreement, dated July 15, 2017, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March... (Filed With SEC on September 3, 2019)
- Amendment 4 to Sub-License and Collaboration Agreement, dated August 29, 2016, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated... (Filed With SEC on September 3, 2019)
- Amendment 3 to Sub-License and Collaboration Agreement, dated December 31, 2015, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated... (Filed With SEC on September 3, 2019)
- Amendment 2 to Sub-License and Collaboration Agreement, dated April 27, 2015, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March... (Filed With SEC on September 3, 2019)
- Amendment 1 to Sub-License and Collaboration Agreement, dated April 19, 2013, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March... (Filed With SEC on September 3, 2019)
- Sub-License and Collaboration Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March 20, 2012 (Filed With SEC on September 3, 2019)
- Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (Filed With SEC on September 3, 2019)
